Secretin regulatory status
Current status of Secretin in the United States: FDA approved. In sport: Not WADA prohibited. Details, sources, and the dated timeline follow.
By the PeptideAgent Editorial Team. Draft, pending editorial review. Last verified
What is the current status of Secretin?
Regulatory: FDA approvedWADA: Not WADA prohibitedVerified: Verified Sep 23, 2026
- FDA and compounding
- FDA approved diagnostic drug: synthetic porcine secretin (SecreFlo) was approved in 2002 and synthetic human secretin (ChiRhoStim) in 2004; the human product is the one currently marketed. It is a hospital and endoscopy unit agent with no therapeutic indication, so there is no compounding or telehealth market and it is not on any 503A bulks list. Some research chemical sellers list secretin, but there is no evidence based human use outside diagnostic testing.
- WADA
- Not WADA prohibited
- Access path
- Administered intravenously by a gastroenterologist or endoscopist in a hospital or endoscopy unit for pancreatic function testing, gastrinoma testing, or ERCP.
- Not dispensed to patients and not available through compounding pharmacies or telehealth.
Full Secretin page: evidence, dosing in the literature, and sources
How has the status of Secretin changed over time?
No dated regulatory event has been recorded for Secretin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.
Sources
Numbered citations in the answers above point here, followed by the regulatory sources on record for Secretin and the source of each dated event.